Pfizer (PFE) Tops Q4 EPS by 15c, Beats on Revenue; Offers FY25 Guidance

Pfizer (NYSE: PFE) reported Q4 EPS of $0.63, $0.15 better than the analyst estimate of $0.48. Revenue for the quarter came in at $17.8 billion versus the consensus estimate of $17.28 billion.

GUIDANCE:

Pfizer sees FY2025 EPS of $2.80-$3.00, versus the consensus of $2.93. Pfizer sees FY2025 revenue of $61-64 billion, versus the consensus of $63 billion.

For earnings history and earnings-related data on Pfizer (PFE) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Morgan Stanley reports China property sales rise in 50 cities
• BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30